Skip to main content
SpringerLink
Log in

Approaches in the Management of Patients with Chronic Kidney Disease and Cardiovascular Disease

  • Chapter
Cardiorenal Syndrome

  • 1080 Accesses

Abstract

Cardiovascular disease (CVD) risk is increased even in the earliest stages of chronic kidney disease (CKD) and is comparable to that conferred by diabetes. The main causes of death from CVD in CKD patients are a specific form of cardiomyopathy and accelerated atherosclerosis. Although the causes of the high CV risk are not yet fully understood, the main factors responsible for both progression of kidney disease and CV risk are hypertension, dyslipidemia, activation of the renin-angiotensin system and sympathetic nervous system, retention of sodium and phosphate, and vitamin D deficiency. All these factors are susceptible to intervention.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Sarnak MJ, Levey AS, Schoolwerth AC et al (2003) Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 42:1050–1065

    Article  CAS  PubMed  Google Scholar 

  2. Mancia G, De Backer G, Dominiczak A et al (2007) 2007 ESH-ESC practice guidelines for the management of arterial hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 25:1751–1762

    Article  CAS  PubMed  Google Scholar 

  3. Go AS, Chertow GM, Fan D et al (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351:1296–1305

    Article  CAS  PubMed  Google Scholar 

  4. Foley RN, Parfrey PS, Samak MJ (1998) Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32:S112–119

    Article  Google Scholar 

  5. Lindner A, Charra B, Sherrard DJ et al (1974) Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 290:697–701

    Article  CAS  PubMed  Google Scholar 

  6. Wanner C, Krane V, Marz W et al (2005) Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353:238–248

    Article  CAS  PubMed  Google Scholar 

  7. Isbel NM, Haluska B, Johnson DW et al (2006) Increased targeting of cardiovascular risk factors in patients with chronic kidney disease does not improve atheroma burden or cardiovascular function. Am Heart J 151:745–753

    Article  PubMed  Google Scholar 

  8. Stevens LA, Coresh J, Greene T et al (2006) Assessing kidney function—measured and estimated glomerular filtration rate. N Engl J Med 354:2473–2483

    Article  CAS  PubMed  Google Scholar 

  9. Levey AS, Stevens LA, Schmid CH et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150:604–612

    PubMed  Google Scholar 

  10. Shlipak MG, Sarnak MJ, Katz R et al (2005) Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 352:2049–2060

    Article  CAS  PubMed  Google Scholar 

  11. Tonelli M, Jose P, Curhan G et al (2006) Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomised trial. BMJ 332:1426

    Article  PubMed  Google Scholar 

  12. Hallan SI, Ritz E, Lydersen S et al (2009) Combining GFR and albuminuria to classify CKD improves prediction of ESRD. J Am Soc Nephrol 20:1069–1077

    Article  CAS  PubMed  Google Scholar 

  13. Strippoli GF, Craig JC, Schena FP (2004) The number, quality, and coverage of randomized controlled trials in nephrology. J Am Soc Nephrol 15:411–419

    Article  PubMed  Google Scholar 

  14. Moustapha A, Naso A, Nahlawi M et al (1998) Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation 97:138–141

    CAS  PubMed  Google Scholar 

  15. Jamison RL, Hartigan P, Kaufman JS et al (2007) Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. JAMA 298:1163–1170

    Article  CAS  PubMed  Google Scholar 

  16. Pfeffer MA, Burdmann EA, Chen CY et al (2009) A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361:2019–2032

    Article  PubMed  Google Scholar 

  17. Eckardt KU, Berns JS, Rocco MV et al (2009) Definition and classification of CKD: the debate should be about patient prognosis—a position statement from KDOQI and KDIGO. Am J Kidney Dis 53:915–920

    Article  PubMed  Google Scholar 

  18. Klahr S, Levey AS, Beck GJ et al (1994) The effects of dietary protein restriction and bloodpressure control on the progression of chronic renal disease. The Modification of Diet in Renal Disease Study Group. N Engl J Med 330:877–884

    Article  CAS  PubMed  Google Scholar 

  19. Peterson JC, Adler S, Burkart JM et al (1995) Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 123:754–762

    CAS  PubMed  Google Scholar 

  20. Schrier RW, Estacio RO, Esler A et al (2002) Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 61:1086–1097

    Article  PubMed  Google Scholar 

  21. Ritz E, Bakris G (2009) World Kidney Day: hypertension and chronic kidney disease. Lancet 373:1157–1158

    Article  CAS  PubMed  Google Scholar 

  22. Sleight P, Redon J, Verdecchia P et al (2009) Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens 27:1360–1369

    Article  CAS  PubMed  Google Scholar 

  23. Pohl MA, Blumenthal S, Cordonnier DJ et al (2005) Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations. J Am Soc Nephrol 16:3027–3037

    Article  CAS  PubMed  Google Scholar 

  24. Messerli FH, Mancia G, Conti CR et al (2006) Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intem Med 144:884–893

    Google Scholar 

  25. Stefanski A, Schmidt KG, Waldherr R et al (1996) Early increase in blood pressure and dias-tolic left ventricular malfunction in patients with glomerulonephritis. Kidney Int 50:1321–1326

    Article  CAS  PubMed  Google Scholar 

  26. Jafar TH, Schmid CH, Landa M et al (2001) Angiotensin-Converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 135:73–87

    CAS  PubMed  Google Scholar 

  27. de Zeeuw D, Remuzzi G, Parving HH et al (2004) Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENA4.L. Kidney Int 65:2309–2320

    Article  PubMed  Google Scholar 

  28. Nakao N, Yoshimura A, Morita H et al (2003) Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 361:117–124

    Article  CAS  PubMed  Google Scholar 

  29. Mann JF, Schmieder RE, McQueen M et al (2008) Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 372:547–553

    Article  CAS  PubMed  Google Scholar 

  30. Parving HH, Persson F, Lewis JB et al (2008) Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 358:2433–2446

    Article  CAS  PubMed  Google Scholar 

  31. Ritz E, Tomaschitz A (2009) Aldosterone, a vasculotoxic agent—novel functions for an old hormone. Nephrol Dial Transplant 24:2302–2305

    Article  CAS  PubMed  Google Scholar 

  32. Bomback AS, Kshirsagar AV, Klemmer PJ (2009) Renal aspirin: will all patients with chronic kidney disease one day take spironolactone? Nat Clin Pract Nephrol 5:74–75

    Article  CAS  PubMed  Google Scholar 

  33. Bakris GL, Hart P, Ritz E (2006) Beta blockers in the management of chronic kidney disease. Kidney Int 70:1905–1913

    CAS  PubMed  Google Scholar 

  34. Vonend O, Marsalek P, Russ H et al (2003) Moxonidine treatment of hypertensive patients with advanced renal failure. J Hypertens 21:1709–1717

    Article  CAS  PubMed  Google Scholar 

  35. Stenvinkel P, Heimburger O, Lindholm B et al (2000) Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome). Nephrol Dial Transplant 15:953–960

    Article  CAS  PubMed  Google Scholar 

  36. Shoji T, Nishizawa Y, Kawagishi T et al (1998) Intermediate-density lipoprotein as an independent risk factor for aortic atherosclerosis in hemodialysis patients. J Am Soc Nephrol 9:1277–1284

    CAS  PubMed  Google Scholar 

  37. Tonelli M, Moye L, Sacks FM et al (2003) Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Arm Intern Med 138:98–104

    CAS  Google Scholar 

  38. Chang JW, Yang WS, Min WK et al (2002) Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients. Am J Kidney Dis 39:1213–1217

    Article  CAS  PubMed  Google Scholar 

  39. Fellstrom BC, Jardine AG, Schmieder RE et al (2009) Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 360:1395–1407

    Article  CAS  PubMed  Google Scholar 

  40. Wanner C, Ritz E (2008) Reducing lipids for CV protection in CKD patients-current evidence. Kidney Int Suppl:S24–28

    Google Scholar 

  41. Dobnig H, Pilz S, Schamagl H et al (2008) Independent association of low serum 25-hydroxyvitamin d and 1,25-dihydroxyvitamin D levels with all-cause and cardiovascular mortality. Arch Intern Med 168:1340–1349

    Article  CAS  PubMed  Google Scholar 

  42. Teng M, Wolf M, Lowrie E et al (2003) Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 349:446–456

    Article  CAS  PubMed  Google Scholar 

  43. Wolf M, Shah A, Gutierrez O et al (2007) Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 72:1004–1013

    Article  CAS  PubMed  Google Scholar 

  44. Bodyak N, Ayus JC, Achinger S et al (2007) Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc Natl Acad Sci USA 104:16810–16815

    Article  CAS  PubMed  Google Scholar 

  45. Li YC, Kong J, Wei M et al (2002) 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 110:229–238

    CAS  PubMed  Google Scholar 

  46. Block GA, Hulbert-Shearon TE, Levin NW et al (1998) Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 31:607–617

    Article  CAS  PubMed  Google Scholar 

  47. Tonelli M, Sacks F, Pfeffer M et al (2005) Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 112:2627–2633

    Article  CAS  PubMed  Google Scholar 

  48. Ketteier M, Biggar PH (2009) Dietary and pharmacological control of calcium and phosphate metabolism in predialysis stages of chronic kidney disease. Blood Purif 27:345–349

    Article  Google Scholar 

  49. Reinecke H, Brand E, Mesters R et al (2009) Dilemmas in the management of atrial fibrillation in chronic kidney disease. J Am Soc Nephrol 20:705–711

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nierenzentrum/Department Internal Medicine, Ruperto Carola University, Heidelberg, Germany

    Eberhard Ritz

Authors
  1. Eberhard Ritz
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon

    Adel E. Berbari

  2. Clinica Medica Department of Clinical Medicine and Prevention, University of Milano-Bicocca San Gerardo Hospital, Monza, Milan, Italy

    Giuseppe Mancia

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag Italia

About this chapter

Cite this chapter

Ritz, E. (2010). Approaches in the Management of Patients with Chronic Kidney Disease and Cardiovascular Disease. In: Berbari, A.E., Mancia, G. (eds) Cardiorenal Syndrome. Springer, Milano. https://doi.org/10.1007/978-88-470-1463-3_27

Download citation

  • DOI: https://doi.org/10.1007/978-88-470-1463-3_27

  • Publisher Name: Springer, Milano

  • Print ISBN: 978-88-470-1462-6

  • Online ISBN: 978-88-470-1463-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation